[Update on FGFR3 mutation and multiple regional epigenetic silencing (MRES) phenotype in urothelial carcinogenesis].
FGFR3 mutation leads to a constitutive activation of the receptor 3 to Fibroblast Growth Factor. This mutation is early in urothelial carcinogenesis and is strongly associated to low grade papillary tumors. Multiple regional epigenetic silencing (MRES) phenotype corresponds to the transcriptional inactivation of chromosomal regions in muscle invasive bladder cancer, and is strongly associated to the molecular signature of carcinoma in situ. These alterations could be targeted by new specific therapies.
Inserm U955 équipe 7, service d'urologie, université Paris-Est Créteil, CHU Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France. amassonlecomte@gmail.com
A
A
Masson-Lecomte
D
D
Vordos
A
A
de la Taille
Y
Y
Neuzillet
F
F
Radvanyi
Y
Y
Allory
D015415:Biomarkers / Q000097:blood; D002277:Carcinoma / Q000097:blood / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D002278:Carcinoma in Situ / Q000235:genetics; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D044127:Epigenesis, Genetic; D020868:Gene Silencing; D006801:Humans; D009154:Mutation; D010641:Phenotype; D051498:Receptor, Fibroblast Growth Factor, Type 3 / Q000235:genetics*; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D019459:Urothelium / Q000378:metabolism / Q000473:pathology
D015415:Biomarkers; C496365:FGFR3 protein, human; D051498:Receptor, Fibroblast Growth Factor, Type 3